Octave Bioscience Inc continued to gain momentum this week as new data highlighted growing real-world use of its MSDA Test for multiple sclerosis monitoring. A podium presentation by Dr. Darin T. Okuda at the AAN 2026 conference, covered by Multiple Sclerosis News Today, underscored rising visibility for biomarker-based tools in MS care.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
According to Octave, 64% of MSDA Test orders now come from routine monitoring, indicating that neurologists are increasingly embedding the assay into day-to-day disease tracking. Clinicians are also using MSDA scores to guide discussions about starting disease-modifying therapies, positioning the test more firmly within treatment decision workflows.
Dr. Okuda’s team is exploring the MSDA Test in pregnancy and the postpartum period, where objective disease activity measures have historically been limited. This potential expansion into sensitive life stages could broaden the test’s clinical utility and underline its relevance in nuanced care settings.
Octave also emphasized the role of its Octave Cares financial assistance program, noting that roughly 90% of patients reportedly pay $0 for the MSDA Test. By lowering out-of-pocket costs, the program may reduce adoption barriers and support higher testing volumes across U.S. MS centers.
Taken together, the trends point to increasing clinical traction and recurring demand potential for Octave’s MSDA platform in routine MS care. If current patterns hold, the company’s strengthened positioning in biomarker-driven neurology could support its long-term commercial outlook, making this a constructive week for Octave Bioscience Inc.